REQUEST A DEMO
Total
USD $0.00
Search more companies

Upward Pharma Sp. z o.o. (Poland)

Main Activities: Pharmaceutical Preparation Manufacturing
Secondary Activities: Other Miscellaneous Nondurable Goods Merchant Wholesalers | Wholesale Trade Agents and Brokers | Pharmacies and Drug Stores | Department Stores | Administrative Management and General Management Consulting Services | Convention and Trade Show Organizers
Full name: Upward Pharma Sp. z o.o. Profile Updated: May 13, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Polish Download a sample report

Upward Pharma Sp. z o.o. is an enterprise in Poland, with the main office in Warsaw. The company operates in the Pharmaceutical Preparation Manufacturing industry. It was established on May 24, 2019. There was a total negative growth of 34.57% in Upward Pharma Sp. z o.o.’s total assets over the same period.

Headquarters
Ul. Jana Zabinskiego 3/14
Warsaw; Mazowieckie; Postal Code: 02-793

Contact Details: Purchase the Upward Pharma Sp. z o.o. report to view the information.

Basic Information
Outstanding Shares:
Purchase the Upward Pharma Sp. z o.o. report to view the information.
Registered Capital:
Purchase the Upward Pharma Sp. z o.o. report to view the information.
Incorporation Date:
May 24, 2019
Key Executives
Purchase this report to view the information.
President
Ownership Details
Purchase this report to view the information.
75%
Purchase this report to view the information.
25%
Company Performance
Financial values in the chart are available after Upward Pharma Sp. z o.o. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.
Operating profit (EBIT)
97.18%
Net Profit (Loss) for the Period
97.18%
Total assets
-34.57%
Total equity
-4.35%
Return on Equity (ROE)
-81.44%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?